Express Scripts (ESRX) Stock Falling on Possible Humana Sale

NEW YORK (TheStreet) -- Shares of Express Scripts Holding Co (ESRX) closed down 2.34% to $87.14 on heavy volume in Friday's regular trading session, after the company was not mentioned in a Wall Street Journal report as a potential bidder for Humana (HUM) earlier today.

In early April, Express Scripts was mentioned by analysts at Leerink as a potential Humana partner.

"In our view, transactions such as Anthem (ANTM)/Humana, Express Scripts/Anthem, and Express Scripts/Humana are not outside the realm of possibility," the firm wrote in a report last month.

But this afternoon, Aetna (AET) and Cigna  (CI) were named as potential bidders for Humana in an article by The Wall Street Journal.

Express Scripts is a pharmacy benefit management organization.

Separately, TheStreet Ratings team rates EXPRESS SCRIPTS HOLDING CO as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

"We rate EXPRESS SCRIPTS HOLDING CO (ESRX) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins."

If you liked this article you might like

Here's How to Invest Like a Billionaire

The Dow Binges on Earnings

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens